Max Barker
About Max Barker
Max Barker is the Senior Vice President of Legal Affairs and Business Operations, known for his significant contributions in the biotechnology legal sector and his role in major corporate acquisitions.
Max Barker's Professional Title
Max Barker currently holds the position of Senior Vice President, Legal Affairs and Business Operations. His role involves overseeing legal matters and business operations within his current organization. He utilizes his extensive background in law and business to manage a variety of responsibilities.
Max Barker's Education and Expertise
Max Barker earned a B.S. in Accounting from Brigham Young University and a J.D. with Honors from The University of Chicago Law School. He has a strong educational background that includes both finance and law, which has enabled him to navigate complex legal and business landscapes. He is licensed to practice law in California and Washington, and was previously a licensed CPA.
Max Barker's Background in Legal Affairs
Max Barker has a significant background in legal affairs, having served in various key positions at notable organizations. He served as vice president, legal affairs & corporate development at Rainier Therapeutics from 2018 to 2020, where he played a critical role in the negotiation and sale of the company’s lead asset. He also worked as vice president, legal affairs at Cascadian Therapeutics, assisting in the sale of the company to Seattle Genetics in 2018.
Max Barker's Role at Rainier Therapeutics and Cascadian Therapeutics
During his tenure at Rainier Therapeutics from 2018 to 2020, Max Barker served as vice president, legal affairs & corporate development. In this role, he was instrumental in the negotiation and sale of the company’s lead asset. Previously, he worked at Cascadian Therapeutics, a publicly traded oncology company, where he was part of the core team that completed the sale of the company to Seattle Genetics.
Max Barker's Early Career and Law Firm Experience
Max Barker has a robust early career background that includes working in the corporate practices of global law firms Cooley LLP and DLA Piper LLP. His practice focused on serving biotechnology clients ranging from early-stage research companies to publicly traded commercial-stage companies. Additionally, he has experience in the audit and assurance practice of KPMG LLP, allowing him to blend both legal and financial expertise in his professional roles.